Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units.
Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral levodopa is currently the most effective treatment for Parkinson’s disease (PD). However, many patients will suffer fluctuations as the disease progresses. CVT-301, an inhaled levodopa powder, has shown promise in clinical trials for managing OFF periods without severe side effects, yet real-world data are lacking.
objectivesTo assess clinical effectiveness and tolerance of inhaled levodopa in PD patients.
methodsobservational study based on a retrospective chart review of consecutive PD patients treated with inhaled levodopa from April 2023 to May 2024.
resultstwenty-eight patients were included. Twenty (71.4%) reported improvement of OFF symptoms, with benefits appearing within 10 min in most patients. Adverse events were common. Only 2 (7.1%) discontinued treatment due to severe coughing.
conclusionsInhaled levodopa offers rapid improvement in PD symptoms with acceptable tolerance. This real-world study underscores its potential benefit for PD-related fluctuations, widening on demand options for patients inadequately controlled by oral medications.
Indexed as
Identifiers
42010133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.